Statutory Review of the Gene Technology Act 2000
Submission to the Statutory Review of the Gene Technology Act 2000
Agrifood Awareness Australia Limited (AFAA) welcomes the opportunity to make this submission to the Statutory Review of the
Gene Technology Act 2000.
Agrifood Awareness Australia Limited is an industry initiative, established to increase public awareness of, and encourage informed debate and decision-making about gene technology. AFAA is committed to providing quality, factual, science-based information on the use of gene technology in agriculture to allow for informed decisions. AFAA works broadly across the agriculture sector.
THE GENE TECHNOLOGY ACT
The
Gene Technology Act 2000 was developed over a long period of time and with extensive consultation. The result is a world-class, science-based, rigorous gene technology regulatory system, in Australia, administered by the Office of the Gene Technology Regulator (OGTR). The Gene Technology Act provides for the transparent and science-based regulation.
A NATIONAL SCHEME
The Gene Technology Act was intended to establish a nationally consistent gene technology regulatory scheme in Australia and this is underpinned by an Inter-Governmental Agreement (between Federal, State and Territory Governments). The Inter-Governmental Agreement makes several references to a national scheme however AFAA believes this has not been achieved due to State Government legislations around markets and trade.
State Governments have implemented legislation around market access considerations for GM crops, with each State Government taking a difference approach - providing no consistency or transparency of decision-making. For those organisations, both public and private, who have invested in gene technology R&D, this provides no path-to-market for approved GM products, despite entities satisfying the Gene Technology Act and gaining OGTR approval.
GM canola - a case study
Genetically modified (GM) canola provides the opportunity to examine the situation and the break-down in a national approach. Following OGTR approval in 2003, a five-year delay occurred until GM canola was planted, in New South Wales and Victoria, in 2008. Western Australian growers waited another two years to gain approval from the State Government to plant GM canola, and South Australian farmers are still banned from growing GM canola approved by Australian and other regulatory authorities around the world, due to SA legislations supposed related to market and trade considerations.
The commercialisation of GM canola, to provide choice for agriculture, was endorsed by 29 organisations from across the grain supply chain. These organisations have demonstrated their commitment and supply chain capacity, having delivered 'market choice' with GM canola since 2008. Despite this demonstration of the supply chain's capacity, South Australian agriculture continues to be denied the GM canola choice.
A study conducted between 2003-2007, by Norton and Roush, entitles "Canola and Australian Farming Systems" (
http://www.jcci.unimelb.edu.au/Canola2007.pdf) estimated that the bans preventing GM canola planting during that time, cost the economy &157 million per annum.
EMERGING TRENDS
To date, approved GM crops in Australia have been modified for insect resistance or herbicide tolerance, or a combination of these (referred to as "stacked traits"). Future GM crops are likely to include both agronomic and quality traits.
In the next five to seven years we are likely to see GM crops under research and development with traits for herbicide tolerance, insect resistance, nitrogen utilisation and nitrogen use efficiently, high yield, stress tolerance (such as drought and frost). improved feed quality, nematode resistance, and modified starch composition. Future crops are also likely to contain more than two stacked traits. It is important for the Gene Technology Act, and the OGTR, to remain abreast of these future developments and ensure the necessary capacity and expertise to assess these products.
COMMUNICATION
The OGTR has undertaken considerable consultation in relation to gene technology R&D and GM crops under development. This has been achieved through a variety of means including advertising, electronic notifications, media, participation in events and face-to-face dialogues with stakeholders. AFAA believes that communication has been both transparent and timely, and had improved considerably since the last
Gene Technology Act review conducted in 2006. AFAA encourages continued communication efforts to build community understanding of, and confidence in, Australia's gene technology regulatory system.
STATUTORY ADVISORY COMMITTEES
It is crucial that Australia's gene technology legislation remain science-based, rather than incorporating value-based judgements. The incorporation of value-based judgements would weaken the OGTR's science-based focus.
AFAA acknowledges the expertise-base of the Statutory Advisory Committees - both the Gene Technology Technical Advisory Committee and the Gene Technology Ethics and Community Consultative Committee (GTECCC). AFAA supports the GTECCC's engagement in ethical and community consultation, rather than in the case-by-base assessment of GM products.
REGULATORY BURDEN AND COMPLIANCE COSTS
The OGTR must be cost effective and decision-making must continue to be transparent. Gene technology in Australia is still at an early phase, so until a substantial number of products reach the market place and deliver a return on investment, AFAA believes the operations of the OGTR should continue to be supported by Government. It is also important that costs of gene technology regulation should not be prohibitive for potential for technology developers (both large and small organisations) and that any costs should be relevant to the potential risk and unnecessary costs should not be places on R&D providers.
Original submission in PDF format (PDF 46 KB)
In this section
- Occasional papers series
- Plasma Fractionation Review
- Regulatory Plan 2007-08
- Regulatory Plan 2008-09
- Regulatory Plan 2006-07
- Department of Health Reconciliation Action Plan
- PHERP Review Reports
- Margaret River Consumer for GM Free Food Submission to the review Gene Technology Act 2000
- 2002 Reviews of the National HIV/AIDS and Hepatitis C Strategies and Strategic Research
- 2006 Aged Care Homes Survey
- 2006 – 2007 Jurisdictional Summary Report against the National Strategic Framework for Aboriginal and Torres Strait Islander Health (NSFATSIH)
- A National Aboriginal Health Strategy: An Evaluation 1994
- An analysis of research on preventing falls and falls injury in older people: Community, residential care and hospital settings (2004 update)
- Anorexia nervosa: Australian treatment guide for consumers and carers, 2005
- Building on success 1: a review of gay and other homosexually active men's HIV/AIDS education in Australia
- Building on success 2: towards a national strategy for HIV/AIDS health promotion for gay and other homosexually active men
- Building on success 3: the Commonwealth Government response to towards national strategy for HIV/AIDS health promotion for gay and other homosexually active men
- COAG mental health early intervention measure - early childhood component: study to scope potential service delivery
- Coping with depression: Australian treatment guide for consumers and carers, 2005
- Council Of Grain Grower Organisations submission to the Gene Technology Act 2000 Review
- Deakin University submission to the Gene Technology Act 2000 review
- Deep vein thrombosis and air travel
- Department of Health and Ageing (DoHA) - Medicare Australia Memorandum of Understanding (MoU)
- Discussion Document Towards a Fourth National HIV/AIDS Strategy April 1999
- Drug and Alcohol Service Report (DASR): 2006-2007 Key Results
- Drug and Alcohol Service Report (DASR): 2007-2008 Key Results
- Evidence of effective interventions to improve the social and environmental factors impacting on health: Informing the development of Indigenous Community Agreements
- Falls prevention activities for older people: a national stocktake
- Gene technology Act 2000 review from Guy Izzett
- gettin em n keepin em
- Government response to the House of Representatives Inquiry into Indigenous health: 'Health is life'
- Innovative grants program: project summaries
- MAIF Guidelines - Marketing Of Infant Formulas Via Electronic Media
- Measuring Remoteness: Accessibility/Remoteness Index of Australia (ARIA) Revised Edition. Occasional Papers: New Series Number 14
- National evaluation of the Sharing Health Care Initiative demonstration projects
- National HIV/AIDS Strategy 2005-2008: Implementation Plan
- National Strategic Framework for Aboriginal and Torres Strait Islander Health Context July 2003
- National strategy for heart, stroke and vascular health in Australia
- Panic disorder and agoraphobia: Australian treatment guide for consumers and carers, 2005
- Principles for the consideration of interactions with health care professionals for the purpose of interpreting the MAIF Agreement
- Public discussion paper - Adoption of the Globally Harmonised System for Classification and Labelling of Chemicals in Respect to Domestic and Consumer Chemicals Including Pesticides
- Quality Use of Pathology Program (QUPP) Historical Reports
- Reforming the Australian
health care system:
the role of government. Occasional Papers: New Series Number 1
- Regulatory Plan 2009-10
- Regulatory Plan 2010-11
- Regulatory Plan 2011-2012
- Review of 2011 Gene Technology ACT (2000) - Public Submission
- Review of the Gene Technology Act 2000
- Review of the Gene Technology Act 2000 by Anne Goddard
- Review of the Gene Technology Act 2000 from I F Turnbull
- Review of the Gene Technology Act 2000 from Slater & Gordon Lawyers on behalf of The Safe Food Institute
- Royal Perth Hospital Comments on the Gene Technology Review 2000
- Self-harm: Australian treatment guide for consumers and carers, 2005
- Stigma and discrimination
- Strong Fathers Strong Families
- Submission by Anne Goddard regarding Terms of Reference in the Gene Technology Act 2000
- Submission by Dr Monica Leggett to the Gene Technology Act 2000 review
- Submission by the Office of the Gene Technology Regulator to the Review of the Gene Technology Act 2000
- Submission by The University of Newcastle for the 2011 Review of the Gene Technology Act 2000
- Submission from Bayer CropScience to the Gene Technology Act 2000 Review
- Submission from AgForce to the Statutory Review of the Gene Technology Act 2000
- Submission from Agrifood Awareness Australia Limited reviewing the Gene Technology Act 2000
- Submission from an Individual to the Review of Gene Technology Act 2000
- Submission from an Individual to the Review of the Gene Technology Act 2000
- Submission from AusBiotech to the 2011 Review of the Gene Technology Act 2000 (the Act)
- Submission from Beatrice Ludwig to the 2011 Review of the Gene Technology Act
- Submission from Croplife Australia to the Review of the Gene Technology Act 2000
- Submission from Department of Agriculture, Fisheries and Foresty to the Review of the Gene Technology Act 2000
- Submission from Elizabeth Hamilton to the 2011 Review of the Gene Technology Act 2000
- Submission from Graham Wearne to the Gene Technology Act 2000 Review
- Submission from Individuals at the Institutional Biosafety Committee to the Gene Technology Act 2000 Review
- Submission from Individuals to the Review of Gene Technology Act 2000
- Submission from Monsanto to the Review of the Gene Technology Act 2000
- Submission from Nuseed Australia to the Review of the Gene Technology Act 2000
- Submission from Peter Olson to the Review of Gene Technology Act 2000
- Submission from Queensland Institute of Medical Research to the Review of Gene Technology Act 2000
- Submission from the Australian Seed Federation to the Statutory Review of the Gene Technology Act 2000
- Submission from the Department of Innovation, Industry, Science and Research and The Commonealth Scientific and Industrial Research Organisation to the 2011 Review of the Gene Technology Act (2000)
- Submission from the Gene Technology Interdepartmental Committee to the Review of the Gene Technology Act 2000
- Submission from the GM-free Australia Alliance to the Review of the Gene Technology Act 2000
- Submission from the Grains Research and Development Corporation to the 2011 Review of the Gene Technology Act 2000
- Submission from the National Association for Sustainable Agriculture Australia WA Inc to the Review of the Gene Technology Act 2000
- Submission from the National Farmers' Federation review to the Gene Technology Act 2000
- Submission from the Producers Forum to the Review of the Gene Technology Act 2000
- Submission from the Western Australian Farmers Federation Review of the Gene Technology Act 2000
- Submission to the Gene Technology Act 2000 Review by Mary Gardner
- Submission to the Gene Technology Act 2000 Review from the Minister for Primary Industries and Water
- Submission to the Review of Gene Technology Act 2000 from Phil Aitken
- Submission to the Review of Gene Technology Act 2000 from Organic and Biodynamic Meats
- Submission to the Review of Gene Technology Act 2000 from Tracey Skippings
- Sumbission from Individuals from the Wambyn Organic Olive Farm for the Gene Technology Act 2000
- Sumission to the Department of Health and Ageing from the Pioneer Hi-Bred Australia Pty Ltd to the Review of the Gene Technology Act 2000 (the Act)
- Technology, Health and Health Care. Occasional Papers: Health Financing Series Volume 5
- The Ageing Australian Population and Future Health Costs: 1996-2051. Occasional Papers: New Series Number 7
- The Australian Government Response to the 2002 Reviews of the National HIV/AIDS and Hepatitis C Strategies
- The Dairy Industry Submission to the Statutory Review of the Gene Technology Acy 2000
- The National Hepatitis C Strategy 2005-2008
- The National Slips and Falls Prevention Project
- The Quality of Australian Healthcare: Current Issues and Future Directions. Occasional Papers: Health Financing Series Volume 6
- The Use of Antibiotics in Food-Producing Animals: Antibiotic-Resistant Bacteria in Animals and Humans
- Using Mathematical Models to Assess Responses to an Outbreak of an Emerged Viral Respiratory Disease
- Valuing the past ... investing in the future- Evaluation of the National HIV /AIDS Strategy 1993-94 to 1995-96
- Trachoma Surveillance Report 2006 to 2010
- Regulatory Plan 2005-06
- Regulatory Plan 2004-05
- Regulatory Plan 2003-04